Daiichi Sankyo launches antihypertensive agent olmesartan in Mexico

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that its subsidiary, Daiichi Sankyo Mexico S.A. DE C.V. (hereafter, Daiichi Sankyo Mexico), has launched the Daiichi Sankyo Group’s leading antihypertensive franchise olmesartan medoxomil in Mexico under the name, Openvas®. It has also launched Openvas Co®, a combination preparation for use with a diuretic*.

Daiichi Sankyo Mexico was established in 2011 to leverage the Group’s Hybrid Business Model in Mexico to offer both innovative and established medicines in Latin America’s second largest market. Openvas® and Openvas Co® are the first innovative pharmaceuticals marketed in Mexico by a Daiichi Sankyo Group company.

Through the marketing of both agents, Daiichi Sankyo Mexico will contribute to treatment of hypertension in Mexico.

*For use with hydrochlorothiazide, a thiazide diuretic